Expression of CD73 in breast cancer and the correlation with its clinicopathological features

Abstract

Abstract:

AIM: To investigate the expression of CD73 in breast cancer and the correlation with its clinicopathological features. METHODS: Biopsy of the tumor tissue specimens from 100 cases of breast cancer from April 2015 to October 2016 were included; Paraffin sections were obtained from 60 normal breast tissues; CD73 staining was used to detect the sections by immunohistochemistry; Immunohistochemical method was used to detect the expression of Ki-67, P53, ER, PR and HER-2 in breast tissues. The expression of CD73 and its correlation with Ki-67, P53, ER, PR and HER-2 as well as correlation with clinicopathological features were analyzed. RESULTS:The high expression occurrence rate of CD73 in breast cancer tissues was 76%, while in normal breast tissue was 21.7% (P<0.05);There was no significant correlation between CD73 expression and age, histological grade, tumor size and tumor location (P>0.05);The high expression of CD73 was correlated with TNM stage, lymph node metastasis, PR positive expression, ER positive expression, HER-2 positive expression, Ki-67 positive expression and P53 positive expression (P<0.05);The positive expression of Ki-67, P53, PR and HER-2 was the influencing factor of the high expression of CD73(OR:8.233,5.091,4.670,3.000); The positive expression of ER was a protective factor of high expression of CD73 (OR: 0.291). CONCLUSION: The high expression of CD73 in breast cancer and TNM staging, lymph node metastasis, the positive expression of PR, HER-2, Ki-67 and P53 are referential for clinical treatment and prognosis.

Key words: CD73, breast cancer, clinicopathological characteristics, biological indexes

CLC Number:

R737.9

YU Kun, NI Chao, SONG Xiangyang, YUAN Hongjun, SUN Kewang. Expression of CD73 in breast cancer and the correlation with its clinicopathological features[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 551-555.

References

［1］令狐锐霞, 司文, 李莹,等. 3846例乳腺癌流行病学及临床病理学分析［J］. 解放军医学院学报, 2015(10):1017-1021.
［2］Turcotte M, Spring K, Pommey S, et al. CD73 is associated with poor prognosis in high-grade serous ovarian cancer［J］. Cancer Res, 2015, 75(21):4494-4503.
［3］Liu XH, Wu XR, Chen YF, et al. Abstract 2938: Role of CD73 in promoting metastasis and resistance to 5-fluorouracil of colorectal cancer［J］. Cancer Res, 2016, 76(14):2938-2938.
［4］胡坚, 王雷, 彭储芬,等. CD73在宫颈癌组织中的表达及其意义［J］. 医学临床研究, 2015, 32(9):1810-1812.
［5］王丽, 李录英, 陆齐,等. CD73在乳腺癌血管新生中的作用［J］. 中国病理生理杂志, 2015(10):1843-1843.
［6］Buisseret L, Garaud S, Allard B, et al. Abstract 3361: CD73 expression on tumor-infiltrating breast cancer leukocytes［J］. Cancer Res, 2015, 75(15):3361-3361.
［7］Fromowitz FB, Viola MV, Chao S, et al. ras p21 expression in the progression of breast cancer［J］. Hum Pathol, 1988, 18(12):1268-1275.
［8］邢秀月. CD73在宫颈癌中的表达及临床意义［J］. 中国现代医学杂志, 2015, 25(32):55-58.
［9］何金霞. CD73在结直肠癌细胞侵袭转移中的作用及相关分子机制研究［D］. 第三军医大学, 2014.
［10］王丽, 李录英, 陆齐,等. CD73在乳腺癌血管新生中的作用［J］. 中国病理生理杂志, 2015(10):1843.
［11］石源源, 刘丽, 高程凤,等. CD73在肿瘤中的研究进展［J］. 中国当代医药, 2010, 17(22):13-14.
［12］胡坚, 王雷, 彭储芬,等. CD73在宫颈癌组织中的表达及其意义［J］. 医学临床研究, 2015, 32(9):1810-1812.
［13］Louis NA, Robinson AM, Macmanus CF, et al. Control of IFN-αA by CD73: Implications for Mucosal Inflammation［J］. J Immunol, 2014, 180(6):4246.
［14］ Mei C, Ding H, Chen F, et al. Mdivi-1 protects against ischemic brain injury via elevating extracellular adenosine in a cAMP/CREB-CD39-dependent manner［J］. Mol Neurobiol, 2016, 53(1):240-253.
［15］Burghoff S, Gong X, Viethen C, et al. Growth and metastasis of B16-F10 melanoma cells is not critically dependent on host CD73 expression in mice［J］. BMC Cancer, 2014, 14(1):898.
［16］马思宇. CD73在卵巢上皮性癌组织中的表达及与微血管密度相关性研究［D］. 吉林大学, 2016.
［17］李文华, 张莹. 乳腺癌复发转移灶与原发灶中ER、PR、HER-2、p53、Ki-67的表达差异［J］. 临床与实验病理学杂志, 2016, 32(7):727-730.

[1]	HE Lihua, ZHU Xiuzhi, JIANG Yizhou. Research progress on immunotherapy for triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
[2]	ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin. Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
[3]	FU Xiaoyu, KONG Deguang, LI Juanjuan. Treatment progress of triple positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 866-875.
[4]	LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui. Advances in targeted therapy for HER2-positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
[5]	XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua. Research progress of biomarkers related to the efficacy of HER2 positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897.
[6]	CHEN Keyu, HUANG Yuan, WANG Xiaojia, ZHENG Yabing. Clinical application and research progress of antibody drugs conjugation in breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 898-909.
[7]	LI Mengxi, ZHANG Kejing, XIA Fan. Research progress in vaccine for breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 918-925.
[8]	WANG Zhi, ZHOU Xin, HE Xueru, FU Yuhao, XUN Xuejiao, LI Ying, DONG Zhanjun. Clinical research progress of palbociclib in treatment of breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 205-213.
[9]	WANG Xiu, JI Qilin, PEI Wenjun, ZENG Ying. 3-bromopyruvate cholesterol ester enhances the sensitivity of breast cancer cells to tamoxifen [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1093-1100.
[10]	WU Shuai, YANG Jun, ZHENG Yun. Dual role of miRNA in breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 814-821.
[11]	SHI Jingbin, XIONG Yang. Research progress on interaction between tumor microenvironment and breast cancer cells leading to tumor metastasis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 562-574.
[12]	DONG Wei, HUANG Xiaoying, XIE Bingbin, TANG Xilan, LI Hongming, QIU Yumei, ZHAO Guowei, LIANG Xinli. Effects of oxypeucedanin on the resistance of breast cancer MCF-7/DOX cells to doxorubicin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 260-266.
[13]	XU Guofang, ZHANG Sisen, LIU Ping, MEI Jiazhuan, LIU Weiwei, LIU Ya'ou, QI Qi. Population pharmacokinetics of capecitabine in Chinese breast cancer patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 552-559.
[14]	SUN Hong, HOU Jialin, CAI Jiaqin, WEI Xiaoxia, ZHUANG Jie. SUMO E3 ligase mediates androgen receptor transcription to promote tamoxifen resistance of breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 285-291.
[15]	JIN Le, JIANG Duochen, CHEN Hongxiao, LIU Su, CHEN Zhaolin, JU Jing. Quercetin reverses adriamycin resistance by activating GSK-3β/β-catenin pathways through GAS5 in breast cancer cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1344-1351.